In a report released on March 13, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA (ACIU – Research Report), with a price target of $16.00.
Andrew Fein’s rating is based on the promising developments in AC Immune SA’s ACI-7104 program, which has shown a significant increase in anti-alpha-synuclein antibodies after immunization. The interim data suggests a strong immunogenicity profile, with the potential for a robust oligomeric alpha-synuclein binding profile in future updates. This could facilitate the progression to the next phase of clinical trials, particularly the proof-of-concept study in early Parkinson’s Disease.
Additionally, the collaboration with Dr. Klaus Gerwert’s team to utilize the immuno-infrared sensor (iRS) platform enhances the accuracy of measuring target engagement for ACI-7104. The iRS platform has demonstrated high efficacy in differentiating Parkinson’s Disease and multiple system atrophy from controls, which supports the potential of ACI-7104 in addressing neurodegenerative disorders. These factors collectively contribute to Fein’s optimistic outlook and Buy rating for AC Immune SA.
Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Neurocrine, and Vertex Pharmaceuticals. According to TipRanks, Fein has an average return of 2.5% and a 40.69% success rate on recommended stocks.
In another report released on March 14, Leerink Partners also maintained a Buy rating on the stock with a $9.00 price target.